Overexpression of MN1 Confers Resistance to Chemotherapy, Accelerates Leukemia Onset, and Suppresses p53 and Bim Induction

per Pardee, Timothy S.
Publicat 2012

Animal Models of Leukemia: Any closer to the real thing?

per Cook, Guerry J, Pardee, Timothy S.
Publicat 2013

Improving Nucleoside Analogs via Lipid Conjugation; Is fatter any better?

per Alexander, Peter, Kucera, Gregory, Pardee, Timothy S.
Publicat a Crit Rev Oncol Hematol (2016)

Yeast and Human RNA Polymerase II Elongation Complexes: Evidence for Functional Differences and Postinitiation Recruitment of Factors

per Pardee, Timothy S., Ghazy, Mohamed A., Ponticelli, Alfred S.
Publicat 2003

The Flt3 Internal Tandem Duplication Alters Chemotherapy Response In Vitro and In Vivo in a p53-Dependent Manner

per Pardee, Timothy S., Zuber, Johannes, Lowe, Scott W.
Publicat 2011

Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia

per Pang, Changlee S, Pettenati, Mark J, Pardee, Timothy S
Publicat a J Clin Pathol (2015)

Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity

per Jennings-Gee, Jamie, Pardee, Timothy S., Gmeiner, William H.
Publicat 2012

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults

per Klepin, Heidi D., Rao, Arati V., Pardee, Timothy S.
Publicat a J Clin Oncol (2014)

Mitochondria in cancer metabolism, an organelle whose time has come?

per Anderson, Rebecca G., Ghiraldeli, Lais P., Pardee, Timothy S.
Publicat a Biochim Biophys Acta Rev Cancer (2018)

The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML

per Cook, Guerry J., Caudell, David L., Elford, Howard L., Pardee, Timothy S.
Publicat a PLoS One (2014)

Thymineless Death in F10-Treated AML Cells Occurs via Lipid Raft Depletion and Fas/FasL co-Localization in the Plasma Membrane with Activation of the Extrinsic Apoptotic Pathway

per Gmeiner, William H., Jennings-Gee, Jamie, Stuart, Christopher H., Pardee, Timothy S.
Publicat a Leuk Res (2014)

Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome

per Puthiyaveetil, Abdul Gafoor, Reilly, Christopher M., Pardee, Timothy S., Caudell, David L.
Publicat a Leuk Res (2012)

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence

per Gmeiner, William H, Debinski, Waldemar, Milligan, Carol, Caudell, David, Pardee, Timothy S
Publicat a Future Oncol (2016)

The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C()

per Alexander, Peter M., Kucera, Gregory L., Pladna, Kristin M., Pardee, Timothy S.
Publicat a Transl Oncol (2020)

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity

per Pardee, Timothy S., Gomes, Evan, Jennings-Gee, Jamie, Caudell, David, Gmeiner, William H.
Publicat 2012

The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells

per Pardee, Timothy S., Stadelman, Kristin, Jennings-Gee, Jamie, Caudell, David L., Gmeiner, William H.
Publicat 2014

The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia

per Alexander, Peter M., Caudell, David L., Kucera, Gregory L., Pladna, Kristin M., Pardee, Timothy S.
Publicat a PLoS One (2017)

Comorbidity, age and mortality among adults treated intensively for acute myeloid leukemia (AML)

per Tawfik, Bernard, Pardee, Timothy, Isom, Scott, Sliesoraitis, Sarunas, Winter, Allison, Lawrence, Julia, Powell, Bayard L., Klepin, Heidi D.
Publicat a J Geriatr Oncol (2015)

Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia

per Kuhlman, Patrick, Isom, Scott, Pardee, Timothy S., Burns, Cynthia, Tawfik, Bernard, Lamar, Zanetta S., Powell, Bayard L., Klepin, Heidi D.
Publicat a Support Care Cancer (2018)

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pa...

per Philip, Philip A, Buyse, Marc E, Alistar, Angela T, Rocha Lima, Caio MSP, Luther, Sanjeev, Pardee, Timothy S, Cutsem, Eric Van
Publicat a Future Oncol (2019)